Literature DB >> 25529877

Determination of the antimalarial drug piperaquine in small volume pediatric plasma samples by LC-MS/MS.

Linda L Kjellin1, Grant Dorsey, Philip J Rosenthal, Francesca Aweeka, Liusheng Huang.   

Abstract

AIM: Determination of piperaquine (PQ) in pediatric plasma requires a method with a small sample volume.
RESULTS: We report a sensitive LC-MS/MS method for quantitation of PQ with only 25 µl human plasma. Using a deuterated internal standard (PQ-d6), an analytical PFP column, APCI(+) as the ion source and MRM (535/288 for PQ and 541/294 for the IS) for detection, the method has a linear calibration range of 1.5-250 ng/ml with a runtime of 3.0 min per sample. The method was applied to plasma samples from children.
CONCLUSION: The developed LC-MS/MS method is suitable for pediatric studies with small volume plasma samples collected via capillary tubes. One limitation was the performance of PFP columns varied among different brands.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25529877      PMCID: PMC4321809          DOI: 10.4155/bio.14.254

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  20 in total

1.  Automated solid-phase extraction method for the determination of piperaquine in plasma by peak compression liquid chromatography.

Authors:  N Lindegårdh; M Ashton; Y Bergqvist
Journal:  J Chromatogr Sci       Date:  2003-01       Impact factor: 1.618

2.  Systematic investigation of ion suppression and enhancement effects of fourteen stable-isotope-labeled internal standards by their native analogues using atmospheric-pressure chemical ionization and electrospray ionization and the relevance for multi-analyte liquid chromatographic/mass spectrometric procedures.

Authors:  Daniela Remane; Dirk K Wissenbach; Markus R Meyer; Hans H Maurer
Journal:  Rapid Commun Mass Spectrom       Date:  2010-04-15       Impact factor: 2.419

3.  Increased risk of early vomiting among infants and young children treated with dihydroartemisinin-piperaquine compared with artemether-lumefantrine for uncomplicated malaria.

Authors:  Darren Creek; Victor Bigira; Emmanuel Arinaitwe; Humphrey Wanzira; Abel Kakuru; Jordan Tappero; Moses R Kamya; Grant Dorsey; Taylor G Sandison
Journal:  Am J Trop Med Hyg       Date:  2010-10       Impact factor: 2.345

4.  Comparison of plasma, venous and capillary blood levels of piperaquine in patients with uncomplicated falciparum malaria.

Authors:  Elizabeth A Ashley; Kasia Stepniewska; Niklas Lindegardh; Anna Annerberg; Joel Tarning; Rose McGready; Lucy Phaiphun; Pratap Singhasivanon; Nicholas J White; François Nosten
Journal:  Eur J Clin Pharmacol       Date:  2010-03-19       Impact factor: 2.953

5.  Determination of lumefantrine in small-volume human plasma by LC-MS/MS: using a deuterated lumefantrine to overcome matrix effect and ionization saturation.

Authors:  Liusheng Huang; Xiaohua Li; Florence Marzan; Patricia S Lizak; Francesca T Aweeka
Journal:  Bioanalysis       Date:  2012-01       Impact factor: 2.681

6.  Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria.

Authors:  Khin Maung Lwin; Aung Pyae Phyo; Joel Tarning; Warunee Hanpithakpong; Elizabeth A Ashley; Sue J Lee; Phaikyeong Cheah; Pratap Singhasivanon; Nicholas J White; Niklas Lindegårdh; François Nosten
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

7.  In vitro metabolism of piperaquine is primarily mediated by CYP3A4.

Authors:  Tina Ming-Na Lee; Liusheng Huang; Marla K Johnson; Patricia Lizak; Deanna Kroetz; Francesca Aweeka; Sunil Parikh
Journal:  Xenobiotica       Date:  2012-06-06       Impact factor: 1.908

8.  Efficacy, safety, and tolerability of three regimens for prevention of malaria: a randomized, placebo-controlled trial in Ugandan schoolchildren.

Authors:  Joaniter Nankabirwa; Bonnie Cundill; Sian Clarke; Narcis Kabatereine; Philip J Rosenthal; Grant Dorsey; Simon Brooker; Sarah G Staedke
Journal:  PLoS One       Date:  2010-10-19       Impact factor: 3.240

9.  Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants.

Authors:  Darren J Creek; Victor Bigira; Shelley McCormack; Emmanuel Arinaitwe; Humphrey Wanzira; Abel Kakuru; Jordan W Tappero; Taylor G Sandison; Niklas Lindegardh; Francois Nosten; Francesca T Aweeka; Sunil Parikh
Journal:  J Infect Dis       Date:  2013-02-27       Impact factor: 5.226

10.  Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children.

Authors:  Jane Achan; Abel Kakuru; Gloria Ikilezi; Theodore Ruel; Tamara D Clark; Christian Nsanzabana; Edwin Charlebois; Francesca Aweeka; Grant Dorsey; Philip J Rosenthal; Diane Havlir; Moses R Kamya
Journal:  N Engl J Med       Date:  2012-11-29       Impact factor: 91.245

View more
  15 in total

1.  Modeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperaquine Preventive Therapy during Pregnancy in Uganda.

Authors:  Erika Wallender; Nan Zhang; Melissa Conrad; Abel Kakuru; Mary Muhindo; Patrick Tumwebaze; Richard Kajubi; Daniel Mota; Jennifer Legac; Prasanna Jagannathan; Diane Havlir; Moses Kamya; Grant Dorsey; Francesca Aweeka; Philip J Rosenthal; Rada M Savic
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

2.  Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin-Piperaquine as Malaria Chemoprevention.

Authors:  Meghan E Whalen; Richard Kajubi; Nona Chamankhah; Liusheng Huang; Francis Orukan; Erika Wallender; Moses R Kamya; Grant Dorsey; Prasanna Jagannathan; Philip J Rosenthal; Norah Mwebaza; Francesca T Aweeka
Journal:  Clin Pharmacol Ther       Date:  2019-07-22       Impact factor: 6.875

3.  Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention.

Authors:  R Kajubi; L Huang; P Jagannathan; N Chamankhah; M Were; T Ruel; C A Koss; A Kakuru; N Mwebaza; M Kamya; D Havlir; G Dorsey; P J Rosenthal; F T Aweeka
Journal:  Clin Pharmacol Ther       Date:  2017-05-30       Impact factor: 6.875

4.  Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz.

Authors:  Erika Wallender; Katarina Vucicevic; Prasanna Jagannathan; Liusheng Huang; Paul Natureeba; Abel Kakuru; Mary Muhindo; Mirium Nakalembe; Diane Havlir; Moses Kamya; Francesca Aweeka; Grant Dorsey; Philip J Rosenthal; Radojka M Savic
Journal:  J Infect Dis       Date:  2018-03-05       Impact factor: 5.226

5.  Determination of unbound piperaquine in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry.

Authors:  Liusheng Huang; Vong Sok; Usman Aslam-Mir; Florence Marzan; Meghan Whalen; Philip J Rosenthal; Francesca Aweeka
Journal:  J Chromatogr Open       Date:  2022-03-14

6.  Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine.

Authors:  Rada M Savic; Prasanna Jagannathan; Richard Kajubi; Liusheng Huang; Nan Zhang; Moses Were; Abel Kakuru; Mary K Muhindo; Norah Mwebaza; Erika Wallender; Tamara D Clark; Bishop Opira; Moses Kamya; Diane V Havlir; Philip J Rosenthal; Grant Dorsey; Francesca T Aweeka
Journal:  Clin Infect Dis       Date:  2018-09-14       Impact factor: 9.079

7.  Effective Antimalarial Chemoprevention in Childhood Enhances the Quality of CD4+ T Cells and Limits Their Production of Immunoregulatory Interleukin 10.

Authors:  Prasanna Jagannathan; Katherine Bowen; Felistas Nankya; Tara I McIntyre; Ann Auma; Samuel Wamala; Esther Sikyomu; Kate Naluwu; Mayimuna Nalubega; Michelle J Boyle; Lila A Farrington; Victor Bigira; James Kapisi; Fran Aweeka; Bryan Greenhouse; Moses Kamya; Grant Dorsey; Margaret E Feeney
Journal:  J Infect Dis       Date:  2016-04-10       Impact factor: 5.226

8.  Piperaquine Exposure Is Altered by Pregnancy, HIV, and Nutritional Status in Ugandan Women.

Authors:  Emma Hughes; Marjorie Imperial; Erika Wallender; Richard Kajubi; Liusheng Huang; Prasanna Jagannathan; Nan Zhang; Abel Kakuru; Paul Natureeba; Moses W Mwima; Mary Muhindo; Norah Mwebaza; Tamara D Clark; Bishop Opira; Miriam Nakalembe; Diane Havlir; Moses Kamya; Philip J Rosenthal; Grant Dorsey; Francesca Aweeka; Radojka M Savic
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

9.  Frequent Malaria Drives Progressive Vδ2 T-Cell Loss, Dysfunction, and CD16 Up-regulation During Early Childhood.

Authors:  Lila A Farrington; Prasanna Jagannathan; Tara I McIntyre; Hilary M Vance; Katherine Bowen; Michelle J Boyle; Felistas Nankya; Samuel Wamala; Ann Auma; Mayimuna Nalubega; Esther Sikyomu; Kate Naluwu; Victor Bigira; James Kapisi; Grant Dorsey; Moses R Kamya; Margaret E Feeney
Journal:  J Infect Dis       Date:  2015-12-13       Impact factor: 5.226

10.  Impact of Intermittent Preventive Treatment During Pregnancy on Plasmodium falciparum Drug Resistance-Mediating Polymorphisms in Uganda.

Authors:  Melissa D Conrad; Daniel Mota; Marissa Foster; Stephen Tukwasibwe; Jennifer Legac; Patrick Tumwebaze; Meghan Whalen; Abel Kakuru; Patience Nayebare; Erika Wallender; Diane V Havlir; Prasanna Jagannathan; Liusheng Huang; Francesca Aweeka; Moses R Kamya; Grant Dorsey; Philip J Rosenthal
Journal:  J Infect Dis       Date:  2017-11-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.